Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Phase 1 Completed
23 enrolled
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Phase 1 Completed
16 enrolled
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Phase 1 Completed
5 enrolled
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Phase 1/2 Completed
49 enrolled 15 charts
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase 1/2 Completed
27 enrolled 13 charts
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
Completed
150 enrolled
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
Phase 2 Completed
12 enrolled 8 charts
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Phase 1 Completed
21 enrolled
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Phase 3 Completed
421 enrolled
PDX+Romi
Phase 1/2 Completed
57 enrolled
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Phase 1/2 Completed
33 enrolled 13 charts
RomiCar
Phase 1/2 Completed
50 enrolled
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Phase 1 Completed
24 enrolled
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
24 enrolled
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Phase 2 Completed
131 enrolled 16 charts
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Phase 1 Completed
15 enrolled 21 charts
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Phase 1 Completed
14 enrolled 21 charts
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Phase 2 Completed
102 enrolled 15 charts
FIL_GEMRO
Phase 2 Completed
20 enrolled 11 charts
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1/2 Completed
51 enrolled 34 charts
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase 1 Completed
26 enrolled
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase 1 Completed
22 enrolled
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 3 Completed
271 enrolled 25 charts
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 Completed
18 enrolled
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Phase 2 Completed
131 enrolled 18 charts
Long-term Use of Romidepsin in Patients With CTCL
Completed
47 enrolled
Depsipeptide in Treating Patients With Solid Tumors
Phase 1 Completed
Ro-CHOP
Phase 1/2 Completed
37 enrolled
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
35 enrolled
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Phase 1 Completed
36 enrolled
FR901228 in Treating Patients With Hematologic Cancer
Phase 1 Completed
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
Phase 2 Completed